



#### MANAGEMENT TEAM & BOARD:

- **Zahed Subhan, PhD**  
MBA JD (CEO & BoD)
- **Peter Hoyle, PhD**  
(Regulatory Consultant)
- **Paul Waymack, MD**  
(Medical Consultant)
- **Colleen Tofani** (Finance)
- **Bobba Venkatadri**  
(VenturEast & BoD)
- **Barbara Schilberg**  
(BioAdvance & BoD)
- **Martin Preuveneers,**  
PhD (BoD)

#### SCIENTIFIC ADVISORS:

- **Frederick Vivino, MD,**  
FACR (Director of the  
Penn Sjögren's  
Syndrome Center &  
Chief, Rheumatology,  
Penn Presbyterian  
Medical Center)
- **Professor Michael**  
**Tweedle, PhD** (Chair,  
Radiology, Ohio State  
University; Former  
President & CEO of  
Bracco Research USA &  
co-inventor of Lu-AMBA)

#### FUNDING TO DATE:

- \$500,000 seed from  
BioAdvance (2005)
- \$1.5M Series A led by  
VenturEast (2006)

#### RAISING:

- \$17-18M to file NDA for  
Pilobuc™ and achieve  
clinical POC for Lu-AMBA

### **Marillion is a clinical-stage oncology pharmaceutical company focused on the development of novel therapeutics**

**About Marillion:** Marillion Pharmaceuticals Inc. is a clinical-stage pharmaceuticals company dedicated to the development and commercialization of novel therapeutics for the treatment of cancers and for supportive care in oncology. Marillion's product pipeline includes Pilobuc™ and Lu-AMBA.

**Pilobuc™:** Pilobuc is a novel, proprietary buccal insert of the marketed muscarinic agonist, pilocarpine, for use in xerostomia (dry mouth), a debilitating loss of salivary gland function associated with radiotherapy for head & neck cancers and various autoimmune disorders including Sjögren's syndrome. The worldwide market for xerostomia products is estimated to be over \$450M. Pilobuc has completed Phase I and Phase II clinical trials in Europe involving over 60 subjects. A US IND was filed in January 2009, with Phase II/III clinical trials expected to begin in the US in 2009 utilizing a 505(b)2 regulatory strategy to accelerate development and approval.

**Lu-AMBA:** Originally developed by Bracco SpA, a billion dollar Italy-based multinational company, Lu-AMBA is a first-in-class receptor-targeted therapeutic agent for the treatment of hormone resistant prostate cancer (HRPC) and advanced metastatic breast cancer. Lu-AMBA is able to deliver a proprietary compound that targets and binds to specific receptors found on certain cancer cells allowing a potent radioactive drug to be internalized by the tumor cells. Subsequently, the tumor is irradiated from within thereby increasing the therapeutic efficacy while helping to protect critical organs. Lu-AMBA can also be used to image cancerous tissue in order to help select patients and adjust the dose used for personalized medicine. Initial proof-of-concept for Lu-AMBA has been demonstrated in advanced HRPC patients in a Phase I trial initiated in the EU. A US IND is expected to be filed by late-2009, with clinical development beginning in the US in early 2010.

#### Attractive Value Proposition

- Two attractive therapeutics with human clinical data
  - Reduced risk xerostomia product with 505(b)2 regulatory strategy and near-term revenue potential
  - First-in-class targeted therapeutic for large solid tumor markets
- Significant published research and issued patents
- Highly cost-efficient operations
- Reasonable funding requirements to achieve significant value inflection points
  - \$8M for Pilobuc™ to file NDA
  - \$9M for Lu-AMBA to achieve Phase II POC
- Minimal capital invested to date
- Three year time horizon to exit